All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAR439859,Palbociclib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The analysis of the efficacy data from the Phase 1b/2 trial combining TG4001 with avelumab in HPV16-positive recurrent and/or metastatic malignancies showed a promising clinical activity in the overall study population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ICT01
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The Independent Safety Review Committee for the Phase I / II EVICTION clinical trial of ImCheck 's lead antibody ICT01, unanimously approved dose escalation in the solid tumour indications and start of enrollment in the other two arms of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TG6002,Flucytosine
Therapeutic Area: Oncology Product Name: TG6002
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TG6002,Flucytosine
Therapeutic Area: Oncology Product Name: TG6002
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Tasly BioPharmaceuticals
Deal Size: $22.2 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2020
Details:
Transgene has been a shareholder in Tasly BioPharmaceuticals when it received shares of Tasly Biopharmaceuticals in exchange for the sale of the Greater China rights of T101 and T601, two products respectively incorporating Transgene’s TG6002 and TG1050 patented technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EO2401
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Symbiosis Pharmaceutical Services LTD
Deal Size: $52.6 Million Upfront Cash: Undisclosed
Deal Type: Financing June 25, 2020
Details:
Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AsiDNA,Niraparib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AsiDNA,Niraparib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
Preclinical data supports the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Cisplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
The Company remains in position to deliver data from its priority pathways in head and neck cancer and immuno-oncology (I/O) on schedule.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABX196,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
Details:
First patient dosed with ABX196, an iNKT (invariant Natural Killer T cell) agonist, in combination with nivolumab.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
